Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To confirm if ketoconazole inhibition of CYP3A activity affects fractional excretion of
docetaxel in the urine.
Secondary Objective:
- To compare the metabolite ratios of the major metabolites of docetaxel in the presence
and absence of CYP3A inhibition.